Ortho Regenerative Technologies entered into a global licensing agreement with Hanuman Pelican for use of the Buoy Suspension Fractional System with Ortho-R, Ortho RTI’s Chitosan-PRP hybrid drug/biologic implant combination product.
The agreement allows exclusive global license (excluding Japan) to use, manufacture, sublicense and sell the Buoy Suspension Fractional System in combination with Ortho-R in the treatment of tendons, ligaments, meniscus, cartilage and wound healing (non-exclusive).
Hanuman will also supply the Buoy Suspension Fractional System as the exclusive Platelet Concentration System to be used in an upcoming U.S. Ortho-R Phase I/II clinical trial for rotator cuff tear repair.
Claude LeDuc, CEO of Ortho RTI, said, “The combination of one of the best PRP systems on the market with our Drug/Biologics implant will enhance our capabilities to deliver a successful Ortho-R U.S. Phase I/II rotator cuff tear repair clinical trial and demonstrate the significant advantages of our approach to soft tissue repair regenerative medicine. …The Buoy Suspension Fractional System in combination with Ortho-R provides us with a complete state-of-the-art turnkey solution that will greatly enhance revenue opportunities for us and facilitate new market penetration initiatives.”
Ortho Regenerative Technologies entered into a global licensing agreement with Hanuman Pelican for use of the Buoy Suspension Fractional System with Ortho-R, Ortho RTI's Chitosan-PRP hybrid drug/biologic implant combination product.
The agreement allows exclusive global license (excluding Japan) to use, manufacture, sublicense and sell the...
Ortho Regenerative Technologies entered into a global licensing agreement with Hanuman Pelican for use of the Buoy Suspension Fractional System with Ortho-R, Ortho RTI’s Chitosan-PRP hybrid drug/biologic implant combination product.
The agreement allows exclusive global license (excluding Japan) to use, manufacture, sublicense and sell the Buoy Suspension Fractional System in combination with Ortho-R in the treatment of tendons, ligaments, meniscus, cartilage and wound healing (non-exclusive).
Hanuman will also supply the Buoy Suspension Fractional System as the exclusive Platelet Concentration System to be used in an upcoming U.S. Ortho-R Phase I/II clinical trial for rotator cuff tear repair.
Claude LeDuc, CEO of Ortho RTI, said, “The combination of one of the best PRP systems on the market with our Drug/Biologics implant will enhance our capabilities to deliver a successful Ortho-R U.S. Phase I/II rotator cuff tear repair clinical trial and demonstrate the significant advantages of our approach to soft tissue repair regenerative medicine. …The Buoy Suspension Fractional System in combination with Ortho-R provides us with a complete state-of-the-art turnkey solution that will greatly enhance revenue opportunities for us and facilitate new market penetration initiatives.”
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
